

## Peer Review File

---

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.



**Open Access** This file is licensed under a Creative Commons Attribution 4.0

International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to

the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. In the cases where the authors are anonymous, such as is the case for the reports of anonymous peer reviewers, author attribution should be to 'Anonymous Referee' followed by a clear attribution to the source work. The images or other third party material in this file are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Editorial Note: This manuscript has been previously reviewed at another journal that is not operating a transparent peer review scheme. This document only contains reviewer comments and rebuttal letters for versions considered at Nature Communications.

Reviewers' Comments:

Reviewer #1:

Remarks to the Author:

My concerns are mostly addressed.

One last minor comment. The statement on line 81-82 that "Treatment with both will reduce viral replication, viral load and ultimately reduce disease severity" does not appear to be justified by any specific data and so should be removed.

**NCOMMS-22-39168-T – Response to reviewers**

**REVIEWERS' COMMENTS**

Reviewer #1 (Remarks to the Author):

My concerns are mostly addressed.

One last minor comment. The statement on line 81-82 that "Treatment with both will reduce viral replication, viral load and ultimately reduce disease severity" does not appear to be justified by any specific data and so should be removed.

Statement removed as requested.